Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and ...

A panelist discusses how real-world experience with ruxolitinib and belumosidil shows similar response rates to clinical trials (45% and 65% respectively), emphasizes the importance of antimicrobial ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell ...

Sam S. Chang MD, MBA, discusses the findings for mitomycin in for low-grade intermediate-risk nonmuscle-invasive bladder ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...